



UNITED STATES PATENT AND TRADEMARK OFFICE

CL
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/733,816	12/10/2003	Stephen D. Harrison	59516-36/PP-15876.009.	8833
27476	7590	06/15/2006	EXAMINER	
Chiron Corporation Intellectual Property - R440 P.O. Box 8097 Emeryville, CA 94662-8097			RAMIREZ, DELIA M	
			ART UNIT	PAPER NUMBER
			1652	

DATE MAILED: 06/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/733,816	HARRISON ET AL.
	Examiner Delia M. Ramirez	Art Unit 1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on ____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-26 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) Claim(s) ____ is/are allowed.
- 6) Claim(s) ____ is/are rejected.
- 7) Claim(s) ____ is/are objected to.
- 8) Claim(s) 1-26 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. ____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. ____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date ____ .	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: ____ .

DETAILED ACTION

Status of the Application

Claims 1-26 are pending.

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1, 3, drawn to a polynucleotide encoding the protein of SEQ ID NO: 2 and a vector comprising said polynucleotide, classified in class 536, subclass 23.2.
 - II. Claim 2, 3, drawn to a polynucleotide encoding the protein of SEQ ID NO: 3 and a vector comprising said polynucleotide, classified in class 536, subclass 23.2.
 - III. Claims 4-7, 16, drawn to the polypeptide of SEQ ID NO: 1, classified in class 435, subclass 194.
 - IV. Claim 8, drawn to the polypeptide of SEQ ID NO: 2, classified in class 435, subclass 194.
 - V. Claim 9, drawn to the polypeptide of SEQ ID NO: 3, classified in class 435, subclass 194.
 - VI. Claims 10-12, drawn to the polynucleotide encoding the protein of SEQ ID NO: 5 and a vector comprising said polynucleotide, classified in class 536, subclass 23.2.
 - VII. Claims 13-15, drawn to the polypeptide of SEQ ID NO: 4, classified in class 435, subclass 194.
 - VIII. Claim 17, drawn to the polypeptide of SEQ ID NO: 5, classified in class 435, subclass 194.
 - IX. Claim 18, drawn to the polynucleotide encoding the polypeptide of SEQ ID NO: 6, classified in class 536, subclass 23.2.

- X. Claim 19, drawn to the polypeptide of SEQ ID NO: 6, classified in class 435, subclass 194.
- XI. Claim 20, drawn to the polynucleotide encoding the polypeptide of SEQ ID NO: 7, classified in class 536, subclass 23.2.
- XII. Claim 21, drawn to the polypeptide of SEQ ID NO: 7, classified in class 435, subclass 194.
- XIII. Claims 22-24, drawn to the polynucleotide encoding the polypeptide of SEQ ID NO: 1, classified in class 536, subclass 23.2.
- XIV. Claims 22, 25-26, drawn to the polynucleotide encoding the polypeptide of SEQ ID NO: 4, classified in class 536, subclass 23.2.

The inventions are distinct, each from the other because of the following reasons:

2. Groups I-XIV each comprise a chemically unrelated structure capable of separate manufacture, use, and effect. The nucleic acids of Groups I-II, VI, IX, XI, XIII-XIV comprise purine and pyrimidine units, and the proteins of Groups III-V, VII-VIII, X, XII comprise amino acids, thus being structurally distinct molecules. The nucleic acids of Groups I-II, VI, IX, XI, XIII-XIV and the proteins of Groups III-V, VII-VIII, X, XII comprise unrelated nucleotide sequences. The nucleic acids of Groups I-II, VI, IX, XI, XIII-XIV have other uses besides encoding the proteins of Groups III-V, VII-VIII, X, XII, such as a hybridization probe or in gene therapy. Further, the proteins of Group III-V, VII-VIII, X, XII can be prepared by processes which are materially different from recombinant expression of the nucleic acids of Groups I-II, VI, IX, XI, XIII-XIV, such as by chemical synthesis, or by isolation and purification from natural sources.

3. As set forth in MPEP § 803, the criteria for a proper restriction between patentably distinct inventions requires that the inventions must be independent or distinct as claimed, and a search of all the inventions would impose a serious burden on the examiner. Groups I-XIV have been shown to be

independent or distinct, for the reasons set forth above. MPEP § 803 also indicates that a serious burden on the examiner may be *prima facie* shown if the Examiner shows by appropriate explanation either separate classification, separate status in the art, or a different field of search. The inventions of Groups I-XIV have acquired a separate status in the art because of their recognized divergent subject matter, as shown by their different classification. In addition, a search of all the inventions would require at a minimum a separate patented/non-patented literature search and a class/subclass search. These searches are not all co-extensive. Therefore a comprehensive examination of all groups would impose an undue burden on the Examiner. Thus, restriction for examination purposes as indicated is proper.

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement can be traversed (37 CFR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

6. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Delia M. Ramirez whose telephone number is (571) 272-0938. The examiner can normally be reached on Monday-Friday from 8:30 AM to 5:00 PM. If attempts to reach the examiner by telephone

Art Unit: 1652

are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy can be reached on (571) 272-0928. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.



Delia M. Ramirez, Ph.D.
Patent Examiner
Art Unit 1652

DR

June 5, 2006